Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Carcinoma
  • Esophageal Neoplasms
  • Neoplasm Recurrence, Local
  • Paclitaxel

abstract

  • Weekly, 96-hour infusion of paclitaxel 60 mg/m(2)/wk, given with concurrent cisplatin and radiotherapy, is a safe and tolerable regimen for patients with localized esophageal cancer. Preliminary efficacy data are encouraging. This regimen is the basis of ongoing Radiation Therapy Oncology Group phase II randomized trials in esophageal and gastric cancers.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.05.039

PubMed ID

  • 14701767

Additional Document Info

start page

  • 45

end page

  • 52

volume

  • 22

number

  • 1